Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06222892 · ClinicalTrials.gov registry record · Phase 1
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
A Phase 1 study of Cough, sponsored by Bellus Health Inc. - a GSK company.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT06222892: Completed Phase 1 study of Cough, sponsored by Bellus Health Inc. - a GSK company.
NCT06222892 is a Phase 1 study of Cough that has completed, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 32 participants, below the 219-participant average among 12 other Cough trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06222892, a Phase 1 study of Cough, has completed, sponsored by Bellus Health Inc. - a GSK company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.
Primary Outcome
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of camlipixant. PK analysis was conducted using standard non-compartmental methods.
Conditions Studied
Interventions
- DRUG Camlipixant
Study Locations (3)
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Orlando
Texas
- GSK Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-02-02 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
What the finished NCT06222892 record still lists
NCT06222892 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 219-participant average among 12 other Cough trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Cough appearing as the primary indexed condition, and to 1 intervention - of which Camlipixant is the first listed.
NCT06222892 reports a single indexed study location in Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06222892 about?
NCT06222892 is a clinical study titled "A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age". The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.
What is the current status of trial NCT06222892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-02-02. Estimated completion is 2024-12-30.
What conditions does trial NCT06222892 study?
This clinical trial studies the following conditions: Cough.
What interventions are being tested in trial NCT06222892?
The interventions under investigation include: Camlipixant (DRUG).
Who is sponsoring clinical trial NCT06222892?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06222892 being conducted?
This trial has 3 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06222892's enrollment target sits among peer trials
32 10th of 12 higher than 3 of 12 other Cough trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cough trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cough Desensitization Therapy: Pilot 2
COMPLETED · Phase 1
-
Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep
COMPLETED · Phase 1
-
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
RECRUITING · Phase 3
-
Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough
RECRUITING
-
The Mechanism Versus PPI Trial
RECRUITING · Phase 4
-
Stimulation of the Larynx to Treat Unexplained Chronic Cough
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI